← Back to Search

Prebiotic

Oligofructose-enriched Inulin OI for Inflammatory Bowel Disease (TII Trial)

N/A
Waitlist Available
Led By Jessica Breton, MD
Research Sponsored by Children's Hospital of Philadelphia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 weeks

Summary

This trial is testing if inulin, a type of dietary fiber, can help children and young adults with IBD by feeding the good bacteria in their gut. The goal is to see if this can reduce their disease symptoms. Inulin is a natural dietary fiber found in many plants and is known for its prebiotic effects, promoting the growth of beneficial gut bacteria.

Eligible Conditions
  • Inflammatory Bowel Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Alteration of gut microbiota and metabolome
Secondary study objectives
Change in fecal calprotectin level

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: InulinExperimental Treatment1 Intervention
Oligofructose-enriched Inulin (OI) administered for 8 weeks
Group II: PlaceboPlacebo Group1 Intervention
Maltodextrin placebo administered for 8 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Oligofructose-enriched Inulin OI
2018
N/A
~60

Find a Location

Who is running the clinical trial?

Children's Hospital of PhiladelphiaLead Sponsor
729 Previous Clinical Trials
8,469,741 Total Patients Enrolled
Beneo GmbHIndustry Sponsor
8 Previous Clinical Trials
350 Total Patients Enrolled
Jessica Breton, MDPrincipal InvestigatorChildren's Hospital of Philadelphia
~7 spots leftby Nov 2025